Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 75
- Reported
- 69
- Verified
- 60
- Gap
- +15
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Strong
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Track; not yet
- Why
- Best-in-class personalized-cancer-vaccine signal with durable 5-year Phase 2b RFS benefit, but pivotal Phase 3 confirmation and a regulatory approval are still pending; not yet a deployable/adoptable product.
- Next
- Monitor INTerpath-001 (Phase 3 adjuvant melanoma) primary readout and FDA/EMA filing timing as the maturity inflection signal
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 0
- Tier 2
- 3
- Tier 3
- 3
- Supports
- 4
- Contradicts
- 2
- Context
- 0
- Latest observed
- 2026-06-01
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.